Oramed (ORMP) to Conduct Sub-Study on Oral Insulin per FDA Request

February 14, 2013 9:29 AM EST Send to a Friend
Get Alerts ORMP Hot Sheet
Trade ORMP Now!
Join SI Premium – FREE
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) has been in communication with the U.S. Food and Drug Administration (FDA) regarding its Investigational New Drug (IND) application for oral insulin. The FDA has asked Oramed to perform a sub study in a controlled in-patient setting for up to a one-week period. In order to accommodate the FDA's request, Oramed will submit a new IND with a clinical protocol for the aforementioned sub study.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA

Add Your Comment